Nuclear factor kappa B (NF-κB) is a family of transcription factors that plays a central role in the inflammatory response and cell survival[1]. The NF-κB pathway is constitutively activated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)[2]. While acute NF-κB activation is protective, chronic activation contributes to neuroinflammation, synaptic dysfunction, and neuronal death.
The NF-κB family in mammals consists of five members: p50 (NF-κB1), p52 (NF-κB2), p65 (RelA), RelB, and c-Rel. These proteins form various homodimers and heterodimers that regulate gene expression programs controlling inflammation, immunity, cell survival, and stress responses[3].
The NF-κB family proteins share a conserved Rel homology domain (RHD) responsible for DNA binding, dimerization, and nuclear localization[4]:
The canonical NF-κB pathway is activated by pro-inflammatory cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (LPS), and cellular stress[5]:
Receptor activation: TNFR1, TLRs, IL-1R activate upstream kinases
IκB kinase (IKK) activation: IKK complex (IKKα, IKKβ, IKKγ/NEMO) phosphorylates IκBα
IκBα degradation: Phosphorylated IκBα is ubiquitinated and degraded by the proteasome
NF-κB nuclear translocation: Free NF-κB dimers (primarily p65/p50) translocate to the nucleus
Gene transcription: NF-κB binds κB sites and activates target gene expression
The alternative (non-canonical) NF-κB pathway is activated by specific cytokines including lymphotoxin-β, CD40 ligand, and BAFF[6]:
NF-κB is the master regulator of inflammatory gene expression[7]. In the brain, it controls expression of:
This response is essential for defense against pathogens and injury. However, chronic activation leads to pathological inflammation.
NF-κB has well-documented anti-apoptotic functions through transcriptional activation of[8]:
In neurons, NF-κB-mediated survival can be protective against various insults. However, the balance between pro-survival and pro-inflammatory effects is context-dependent.
NF-κB is constitutively active at synapses and modulates synaptic plasticity[9]:
NF-κB activation is one of the earliest and most consistent findings in AD brain[10]:
Amyloid-β effects: Aβ oligomers activate NF-κB in neurons and glia, creating a feed-forward inflammatory loop. NF-κB in turn can increase BACE1 expression, promoting amyloidogenesis.
Tau pathology: Hyperphosphorylated tau can activate NF-κB, and NF-κB can promote tau phosphorylation through GSK3β activation.
Microglial activation: Chronic NF-κB activation in microglia drives持续 neuroinflammation. The characteristic "primed" microglia in AD show exaggerated inflammatory responses to secondary challenges.
Neuronal loss: Prolonged NF-κB activation can promote neuronal apoptosis despite initial pro-survival signaling.
NF-κB activation contributes to dopaminergic neuron loss in PD[11]:
Mitochondrial toxins: MPTP and other mitochondrial toxins activate NF-κB in dopaminergic neurons. This activation contributes to cell death.
α-Synuclein pathology: α-Synuclein aggregates can activate NF-κB in neurons and glia. NF-κB activation may promote further aggregation in a vicious cycle.
Microglial activation: Activated microglia in the substantia nigra produce NF-κB-dependent pro-inflammatory cytokines that damage dopaminergic neurons.
Genetic risk factors: PD-associated mutations in genes like LRRK2 and GBA can potentiate NF-κB activation.
NF-κB activation in ALS contributes to motor neuron degeneration[12]:
Motor neuron vulnerability: Motor neurons show sustained NF-κB activation in ALS. This chronic activation promotes inflammatory gene expression and contributes to excitotoxicity.
Astrocytic dysfunction: ALS astrocytes show persistent NF-κB activation that impairs their supportive functions and promotes neurotoxicity.
Microglial activation: Highly activated microglia in ALS produce NF-κB-dependent inflammatory mediators that accelerate motor neuron death.
SOD1 mutations: Mutant SOD1 proteins activate NF-κB, and NF-κB inhibition can slow disease in SOD1 models.
NF-κB plays complex roles in MS pathogenesis[13]:
Demyelination: NF-κB promotes expression of demyelinating factors in immune cells
Blood-brain barrier disruption: NF-κB regulates adhesion molecule expression facilitating immune cell entry
T cell activation: NF-κB is essential for T cell activation and autoimmune responses
However, NF-κB also has protective roles in oligodendrocytes and remyelination, highlighting the pathway's complexity.
Multiple approaches to inhibit NF-κB signaling are being explored[14]:
IKK inhibitors:
IκBα stabilization:
Direct NF-κB inhibition:
Natural compounds:
Therapeutic NF-κB inhibition faces significant challenges[15]:
Safety concerns: NF-κB is essential for immune function and cell survival. Systemic inhibition increases infection risk and may promote tumorigenesis.
Context-dependent effects: NF-κB has both protective and detrimental effects in different cell types and disease stages.
CNS penetration: Many NF-κB inhibitors have poor blood-brain barrier penetration.
Biomarker development: Difficult to assess NF-κB activity in the brain of living patients.
Targeting NF-κB in specific cell types may improve the therapeutic window[16]:
The NF-κB signaling pathway intersects with several neurodegenerative disease mechanisms:
NF-κB signaling is a central pathway in neurodegenerative diseases, contributing to chronic neuroinflammation, synaptic dysfunction, and neuronal death. While acute NF-κB activation is protective, chronic activation creates a self-perpetuating inflammatory state that drives disease progression. Targeting NF-κB therapeutically is challenging due to the pathway's essential physiological functions and complex cell-type-specific effects. However, cell-type-selective approaches and combination therapies offer potential for developing disease-modifying treatments.
The IκB kinase (IKK) complex is the central regulator of canonical NF-κB signaling[1:1]. The complex consists of:
IKK activation occurs through multiple upstream mechanisms:
Receptor-associated kinases: TNFR1, TLR4, and IL-1R recruit TRAF proteins that activate TAK1 kinase, which in turn phosphorylates IKKβ.
Linear ubiquitin chain assembly complex (LUBAC): Generates linear ubiquitin chains on NEMO, essential for full IKK activation.
Phosphorylation and activation: TAK1 phosphorylates IKKβ on Ser177 and Ser181, activating the kinase.
Once activated, IKK phosphorylates IκBα on Ser32 and Ser36, targeting it for ubiquitination and proteasomal degradation. This releases NF-κB dimers (primarily p65/p50) to translocate to the nucleus.
Microglia are the resident immune cells of the brain and primary producers of neuroinflammation in neurodegenerative diseases[2:1].
M1 (classical) activation: LPS and IFN-γ drive classical microglial activation, characterized by NF-κB-dependent production of:
M2 (alternative) activation: IL-4 and IL-13 drive alternative activation, characterized by:
In neurodegenerative diseases, microglia often show a chronic M1-like phenotype with sustained NF-κB activation. This "primed" state shows exaggerated responses to secondary challenges.
Astrocytes respond to injury and disease with reactive astrocytosis, accompanied by NF-κB activation
Reactive astrocytosis:
NF-κB-mediated responses:
Biphasic effects:
Neurons express NF-κB components and respond to various signalsConstitutive activity: Low-level NF-κB activity at synapses is required for normal neuronal function.
Activity-dependent regulation: Synaptic activity stimulates rapid NF-κB nuclear translocation through calcium-dependent mechanisms.
Synaptic scaling: NF-κB mediates homeostatic responses to changes in activity levels.
Dual roles: Both pro-survival and pro-death effects depending on context and duration.
NF-κB and tau pathology are interconnected
Tau activating NF-κB:
Therapeutic implications: Dual targeting of NF-κB and tau may provide synergistic benefits.
Amyloid-β and NF-κB have bidirectional relationships
NF-κB promoting Aβ production:
NF-κB in glial Aβ clearance: NF-κB regulates genes involved in Aβ uptake and degradation.
α-Synuclein pathology activates NF-κB through multiple mechanisms
Neuronal vulnerability: NF-κB activation may make neurons more susceptible to α-synuclein toxicity.
NF-κB target gene expression is regulated by histone modifications- H3K4me3: Mark of active promoters
MicroRNAs re
Long non-coding RNAs also
Several natural products have NF-κB inhibitory activity
Inhibits IKK activity- Blocks NF-κB nuclear translocation
Resveratrol (grapes):
SIRT1 activation inhibits NF-κB
Multiple mechanisms of action
Antioxidant and anti-inflammatory
Sulforaphane (cruciferous vegetables):
Omega-3 fatty acids:
BAY 11-7082:
MLN120B:
PS-1145:
TPCA-1:
Existing drugs with NF-κB activity are being considered for neurodegenerative diseases:
Statins:
Aspirin/Salicylates:
Viral vector delivery of NF-κB inhibitors is being explored
CSF markers:
NF-κB pathw
Imaging approaches for assessing neuroinflammation- MR spectrosc- Advanced MR
##N
In Alzh****Genetic interactions**: PD-associated mutatioNeuroinflammation: Activated microglia s### Amyotrophic Lateral Sclerosis
SOD1 mutations: Mutant SOD1 proteins activate NF-κB in mo
Astrocytic toxicity: ALS astrocytes show constitutive NF-κB activation that impairs their ability to support motor neurons and may promote neurotoxicity
Periphery-CNS communication: Systemic inflammation in ALS (elevated cytokines, acute phase proteins) may prime CNS immune cells through NF-κB-dependent mechanisms.
Therapeutic targeting: NF-κB inhibition has shown benefit in SOD1 mouse models, though systemic inhibition may have limited efficacy.
NF-κB plays complex roles in MS
T cell activation: NF
*
Demyelination: Pro-inflammatory cytokines activate NF-κB in oligodendrocytes, promoting demyelination.
Blood-brain barrier: NF-κB regulates expression of adhesion molecules (VCAM-1, ICAM-1) that facilitate immune cell trafficking into the CNS.
Remyelination failure: NF-κB has biphasic effects on oligodendrocyte precu
NF-κB regulates components of the ubiquitin-proteasome system
NF-κB both regulates and is regulated by autophagy- Autophagy gene regulation: NF-κB activates autophagy genes (Beclin-1, ATG genes)
Endoplasmic reticulum stress activates NF-κB- **Unf##
Developing biomarkers for NF-κB activity in patients is challenging but important**Peripheral blood mononuclear
NF-κB DNA binding activi- Phosphorylated IκBα levels
Ge
Imaging:
TSPO PET: Microglial act- MR spectroscopy: Elevated choline as marker of inflammation
CSF
Successful clinical trials targeting NF-κB will require- Cell-type-se- Appropriate timing in disease course
Given the complexity of neur
Beyond direct NF-κB inhibition, targeting upstream regulators offers opportunities[11:1]
Targeting NF-κB specifically in pathoge
NF-κB signaling stands at the intersection
Hayden, M. S., & Ghosh, S. (2012). NF-κB, the first quarter-century. Immunity. 2012. ↩︎ ↩︎
Shih, R. H., et al. (2015). NF-κB in neurological and neurodegenerative disorders. Mediators of Inflammation. 2015. ↩︎ ↩︎
Zhang, Q., et al. (2017). Structure of NF-κB transcription factor. Cold Spring Harbor Perspectives in Biology. 2017. ↩︎
Oeckinghaus, A., et al. (2011). The NF-κB family of transcription factors. Cold Spring Harbor Perspectives in Biology. 2011. ↩︎
Karin, M., & Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination. Annual Review of Immunology. 2000. ↩︎
Sun, S. C. (2012). The noncanonical NF-κB pathway. Nature Reviews Immunology. 2012. ↩︎
Liu, T., et al. (2017). NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy. 2017. ↩︎
Karin, M., & Lin, A. (2002). NF-κB at the crossroads of life and death. Nature Immunology. 2002. ↩︎
Levenson, J. M., & Rosenberg, M. (2005). NF-κB and synaptic activity. Science. 2005. ↩︎
Chen, C. H., et al. (2012). NF-κB as a therapeutic target in Alzheimer's disease. Journal of Alzheimer's Disease. 2012. ↩︎
Ghosh, A., et al. (2017). NF-κB in Parkinson's disease. Advances in Neurobiology. 2017. ↩︎ ↩︎
Dresselhaus, D., & Meffre, M. K. (2020). NF-κB in amyotrophic lateral sclerosis. Journal of Molecular Neuroscience. 2020. ↩︎
Mc Guire, C., et al. (2018). NF-κB in multiple sclerosis. Frontiers in Neurology. 2018. ↩︎
Gupta, S. C., et al. (2010). Multi-targeting NF-κB pathway. Molecular Cancer Therapeutics. 2010. ↩︎
Tornatore, L., et al. (2012). NF-κB as therapeutic target in neurodegenerative disease. Cell Death & Disease. 2012. ↩︎
Liu, Y., et al. (2019). Cell type-specific NF-κB inhibition. Neuropharmacology. 2019. ↩︎